NUP214 and acute myeloid leukemia: Garcon et al. [5] reported that patients with AML with t(6;9) (p23;q34) who achieved consistent molecular remission, as assessed by real-time quantitative polymerase chain reaction (PCR), showed better survival than patients with persistent DEK-NUP214 positivity, implying a pivotal role for MRD monitoring in this AML subtype.